Zhejiang Huahai Pharmaceutical Overview
- Year Founded
-
1989
- Status
-
Public
- Employees
-
8,797
- Stock Symbol
-
600521
- Investments
-
11
- Share Price
-
$2.33
- (As of Friday Closing)
Zhejiang Huahai Pharmaceutical General Information
Description
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage preparations, biological drugs, innovative drugs, and specialty APIs. The company's products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, torsemide injection, and others.
Contact Information
Website
www.huahaipharm.comCorporate Office
- Xunqiao
- Linhai, Zhejiang 317024
- China
Corporate Office
- Xunqiao
- Linhai, Zhejiang 317024
- China
Zhejiang Huahai Pharmaceutical Stock Performance
As of 20-Nov-2026, Zhejiang Huahai Pharmaceutical’s stock price is $2.33. Its current market cap is $3.5B with 1.5B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.33 | $2.47 | $2.02 - $2.78 | $3.5B | 1.5B | 26.1M | $0.09 |
Zhejiang Huahai Pharmaceutical Financials Summary
As of 30-Sep-2026, Zhejiang Huahai Pharmaceutical has a trailing 12-month revenue of $1.39B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 4,620,723 | 4,529,593 | 4,355,711 | 3,895,504 |
| Revenue | 1,393,277 | 1,194,099 | 1,330,566 | 1,174,397 |
| EBITDA | 202,126 | 231,267 | 354,955 | 292,996 |
| Net Income | 137,210 | 37,045 | 155,946 | 117,382 |
| Total Assets | 3,353,605 | 3,073,301 | 2,775,490 | 2,623,927 |
| Total Debt | 1,272,902 | 1,148,793 | 1,024,423 | 988,821 |
Zhejiang Huahai Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zhejiang Huahai Pharmaceutical Comparisons
Industry
Financing
Details
Zhejiang Huahai Pharmaceutical Competitors (3)
One of Zhejiang Huahai Pharmaceutical’s 3 competitors is Alphamab Oncology, a Formerly VC-backed company based in Suzhou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alphamab Oncology | Formerly VC-backed | Suzhou, China | ||||
| Innovent Biologics | Formerly VC-backed | Suzhou, China | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China |
Zhejiang Huahai Pharmaceutical Patents
Zhejiang Huahai Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026228524-A1 | Composition of donepezil pamoate and preparation method therefor | Pending | 27-Apr-2025 | ||
| WO-2026085702-A1 | 5-substituted indoline chiral amine, preparation method therefor, and use thereof in preparation of silodosin | Pending | 22-Oct-2024 | ||
| WO-2026056878-A1 | Preparation method for pyridazinone compound of thyroid hormone analog and intermediate thereof | Pending | 10-Sep-2024 | ||
| WO-2026051986-A1 | Method for preparing dipeptide compound | Pending | 05-Sep-2024 | ||
| WO-2026040943-A1 | Method for preparing α-chiral carboxylic acid or α-chiral ester by means of enzyme catalysis | Pending | 19-Aug-2024 |
Zhejiang Huahai Pharmaceutical Signals
Zhejiang Huahai Pharmaceutical Investments (11)
Zhejiang Huahai Pharmaceutical’s most recent deal was a Early Stage VC with Starmab Biologies. The deal was made on 05-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Starmab Biologies | 05-Mar-2025 | Early Stage VC | Drug Discovery | ||
| BaiZhen | 18-Jul-2024 | Early Stage VC | Diagnostic Equipment | ||
| DDSome Lab | 06-Jul-2023 | Later Stage VC | Drug Delivery | ||
| Aurealis Therapeutics | 30-Mar-2023 | Later Stage VC | Drug Discovery | ||
| iView Therapeutics | 12-Jan-2022 | Later Stage VC | Drug Discovery |
Zhejiang Huahai Pharmaceutical ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
38.49 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Zhejiang Huahai Pharmaceutical Exits (3)
Zhejiang Huahai Pharmaceutical’s most recent exit was on 06-Jul-2023 from DDSome Lab. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| DDSome Lab | 06-Jul-2023 | Completed |
|
||
| GotoBiopharm | 14-May-2018 | Completed |
|
||
| MicuRx Pharmaceuticals | 26-Sep-2016 | Later Stage VC | Completed |
|
Zhejiang Huahai Pharmaceutical FAQs
-
When was Zhejiang Huahai Pharmaceutical founded?
Zhejiang Huahai Pharmaceutical was founded in 1989.
-
Where is Zhejiang Huahai Pharmaceutical headquartered?
Zhejiang Huahai Pharmaceutical is headquartered in Linhai, China.
-
What is the size of Zhejiang Huahai Pharmaceutical?
Zhejiang Huahai Pharmaceutical has 8,797 total employees.
-
What industry is Zhejiang Huahai Pharmaceutical in?
Zhejiang Huahai Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is Zhejiang Huahai Pharmaceutical a private or public company?
Zhejiang Huahai Pharmaceutical is a Public company.
-
What is Zhejiang Huahai Pharmaceutical’s stock symbol?
The ticker symbol for Zhejiang Huahai Pharmaceutical is 600521.
-
What is the current stock price of Zhejiang Huahai Pharmaceutical?
As of 20-Nov-2026 the stock price of Zhejiang Huahai Pharmaceutical is $2.33.
-
What is the current market cap of Zhejiang Huahai Pharmaceutical?
The current market capitalization of Zhejiang Huahai Pharmaceutical is $3.5B.
-
What is Zhejiang Huahai Pharmaceutical’s current revenue?
The trailing twelve month revenue for Zhejiang Huahai Pharmaceutical is $1.39B.
-
Who are Zhejiang Huahai Pharmaceutical’s competitors?
Alphamab Oncology, Innovent Biologics, and BeOne Medicines are competitors of Zhejiang Huahai Pharmaceutical.
-
What is Zhejiang Huahai Pharmaceutical’s annual earnings per share (EPS)?
Zhejiang Huahai Pharmaceutical’s EPS for 12 months was $0.09.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process